A Practical Guide to the Safety and Monitoring of New IBD Therapies.

A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Click B, Regueiro M Abstract The therapeutic armamentarium of inflammatory bowel disease is rapidly evolving with the development of novel treatment options including targeted monoclonal antibodies and small molecules. With these new therapies come additional safety and side effect concerns. Infections, malignancies, immunogenicity, and metabolic issues exist for each treatment. Management of these agents in the face of such complications is a challenge clinicians will encounter. In this article, we review…

Read More

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H, Feathers A, Rosen MH, Malter LB, Swaminath A, IBD-ReMEdY Study (Research, Mentoring, Education New York) Abstract Background: Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD), often leading to diagnostic confusion and delays in IBD therapy escalation. This study sought…

Read More

Erratum to Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease.

Erratum to Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, Clarke K PMID: 30312402 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30312402?dopt=Abstract

Read More

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflamm Bowel Dis. 2018 Oct 12;24(11):2431-2441 Authors: Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC Abstract Background: Vedolizumab (ENTYVIO) is a humanized α4β7 integrin antagonist approved for the treatment of inflammatory bowel disease, which selectively blocks gut-specific lymphocyte trafficking. We evaluated the risk of opportunistic infections of interest in patients treated with vedolizumab. Methods: We determined the frequency of opportunistic infections and tuberculosis in patients receiving vedolizumab in phase…

Read More

GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD.

GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD. J Crohns Colitis. 2018 Oct 11;: Authors: Dierckx T, Verstockt B, Vermeire S, van Weyenbergh J Abstract Background and aims: Glycoprotein acetylation (GlycA) is a novel nuclear magnetic resonance (NMR) biomarker measured in serum or plasma, which summarizes signal originating from glycan groups of certain acute phase glycoproteins. This biomarker has been shown to be robustly associated to cardiovascular and short-term all-cause mortality, and to disease severity in several inflammatory conditions.…

Read More

Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease. A multivariate analysis in 4 expert centres in Europe.

Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease. A multivariate analysis in 4 expert centres in Europe. J Crohns Colitis. 2018 Oct 11;: Authors: Mege D, Colombo F, Stellingwerf ME, Germain A, Maggiori L, Foschi D, Buskens CJ, de Buck van Overstraeten A, Sampietro G, D’Hoore A, Bemelman W, Panis Y Abstract Background and Aims: Although laparoscopic a1pproach is associated with the reduction of adhesions, no data are available about risk factors for small bowel obstruction (SBO) after laparoscopic ileal pouch-anal anastomosis (IPAA).…

Read More

VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice.

Related Articles VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice. World J Gastroenterol. 2018 Oct 07;24(37):4254-4262 Authors: Wang CS, Li WB, Wang HY, Ma YM, Zhao XH, Yang H, Qian JM, Li JN Abstract AIM: To investigate the effects of VSL#3 on tumor formation, and fecal and intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium (AOM/DSS) induced mice model. METHODS: C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis (UC) carcinogenesis model. Mice were treated with 5-ASA (75 mg/kg/d), VSL#3 (1.5 × 109 CFU/d), or 5-ASA combined with VSL#3 by…

Read More

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.

Related Articles Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting. Dig Dis Sci. 2018 Oct 11;: Authors: Checkley LA, Kristofek L, Kile S, Bolgar W Abstract BACKGROUND: Infliximab is a chimeric anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody that ameliorates inflammation when it binds to and neutralizes TNF-α. It is often used in patients with Crohn’s disease and ulcerative colitis to reduce the severity of disease symptoms and induce disease remission. Infusions are generally administered in the hospital setting due to concerns over patient safety,…

Read More

Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease.

Related Articles Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Dig Dis Sci. 2018 Oct 11;: Authors: Patil SA, Flasar MH, Lin J, Lingohr-Smith M, Skup M, Wang S, Chao J, Cross RK Abstract BACKGROUND: Radiation exposure from diagnostic imaging may increase cancer risk of Crohn’s disease (CD) patients, who are already at increased risk of certain cancers. AIM: To compare imaging radiation exposure and associated costs in CD patients during the year pre- and post-initiation of anti-tumor necrosis factor (anti-TNF) agents or…

Read More

Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study.

Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study. J Crohns Colitis. 2018 Oct 12;: Authors: Nguyen GC, Bouchard S, Diong C, Promoting Access and Care through Centres of Excellence (PACE) Network Abstract Background and Aims: The number of inflammatory bowel disease (IBD) related visits to the emergency department (ED) is increasing in North America. Our study evaluates the relationship between access to specialists and utilization of ED services. Methods: We conducted a population-based study of all IBD patients in the Ontario in 2014-2015 to…

Read More
<< Go Back